Congress keeps SCHIP clean
Executive Summary
The House passed reauthorization for the State Children's Health Insurance Program Jan. 14, clearing the bill without any amendments that would affect the pharmaceutical industry. As a bill with strong support, it could have served as a vehicle for tweaking other government health care programs, such as striking the ban on government interference in drug price negotiations for Medicare Part D, but Congress seems content to wait for the broader health care reform debate to take shape
You may also be interested in...
Next-Gen CAR T & Novel SMA Drug Among New Entrants On EMA’s PRIME
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
GSK's ICOS Agonist Disappointment Another Setback For Anticancer Ambitions
GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.
Teva Identifies ‘Problem Pattern’ Of Complex CRLs Ahead Of GDUFA III
Forecasting up to a dozen complex generic launches by Teva in the US in 2021, executive vice-president for North America commercial Brendan O’Grady said Teva was continuing to push for changes to boost approval rates ahead of GDUFA III next year.